Kidney Disease News and Research

RSS

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

High dose B-vitamin therapy slows progression of diabetic nephropathy: Study

Patients with diabetic nephropathy (kidney disease caused by diabetes) who received high dose B-vitamin therapy experienced a more rapid decline in kidney function and had a higher rate of heart attack and stroke than patients who received placebo, according to a study in the April 28 issue of JAMA.

28 Apr 2010

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the first quarter ended March 31, 2010.

28 Apr 2010

High levels of phosphate in sodas accelerate signs of aging

Here's another reason to kick the soda habit. New research published online in the FASEB Journal shows that high levels of phosphates may add more "pop" to sodas and processed foods than once thought. That's because researchers found that the high levels of phosphates accelerate signs of aging. High phosphate levels may also increase the prevalence and severity of age-related complications, such as chronic kidney disease and cardiovascular calcification, and can also induce severe muscle and skin atrophy.

27 Apr 2010

New DaVita Phosphorus Challenge tool for CKD and dialysis patients

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease, today announced the launch of the DaVita Phosphorus Challenge, an online resource designed to serve as a core learning tool for CKD and dialysis patients.

27 Apr 2010

Black children with chronic kidney disease have severe anemia than white children: Study

Black children with chronic kidney disease have more severe anemia than white children even when they receive the same treatment, according to a multicenter study led by Johns Hopkins Children's Center to be published in the May issue of the American Journal of Kidney Disease.

27 Apr 2010

LFA seeks grant applications from medical researchers to help advance understanding of lupus nephritis

The Lupus Foundation of America seeks grant applications from medical researchers to help advance the understanding of lupus nephritis, a serious and life-threatening complication of lupus that can affect as many as 40 percent of all people with lupus, and two-thirds of children with the disease.

24 Apr 2010

Ampio Pharmaceuticals signs LOI to acquire DMI Biosciences

Ampio Pharmaceuticals, Inc., today announced that it has entered into a letter of intent to acquire DMI Biosciences, Inc.

23 Apr 2010

Mandatory cuts for salt content in processed foods on the horizon

This Tuesday The Institute of Medicine (IOM) has urged the US Food and Drug Administration to start regulating the amount of salt in processed foods. This measure according to them can do what years of advising people to cut down on salt have failed to do.

22 Apr 2010

Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies

Plexxikon Inc. today announced promising preclinical data from in vivo cancer studies with PLX3397 demonstrating significant reduction in tumor burden, metastatic spread, bone erosion and cancer bone pain. PLX3397 is an oral, selective kinase inhibitor that down-modulates macrophages, microglia, osteoclasts and mast cells, all cell types targeted by this drug candidate. These cell types play a key role in cancer and metastasis.

21 Apr 2010

Tips on how to live joyful life with a chronic disease now available in audio version

Award winning speaker and author Lori Hartwell today released a 6-CD unabridged set of her renowned book, Chronically Happy: Joyful Living in Spite of Chronic Illness, which relates her optimism for life despite living with kidney disease for over 40 years.

21 Apr 2010

More testimony on Patel trial

In the ongoing trial of Dr. Jayant Patel for manslaughter of three men and grievous injury to the fourth during his tenure as Director of surgery at Bundaberg base hospital new testimony has surfaced. Patel had pleaded not guilty.

21 Apr 2010

Kaiser Permanente physician to receive ASH Marvin Moser Clinical Hypertension Award

Kaiser Permanente physician Joel Handler, MD, has been selected to receive a national award from the American Society of Hypertension for his "outstanding dedication to the treatment and care of hypertensive patients." The City of Orange resident is a critical care specialist at Kaiser Permanente's Anaheim Medical Center and has served area residents for over 30 years.

21 Apr 2010

CorMedix receives patent for Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cardiorenal disease, today announced that the U.S. Patent and Trademark Office has issued a patent for the use of Neutrolin for preventing infection and clotting in hemodialysis catheters.

21 Apr 2010

RANKL inhibition may prove effective in treatment of human malignancy, suggests study

Amgen today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

20 Apr 2010

Exposure to dust after WTC collapse impairs ability to detect odors and sense irritants

Individuals involved in rescue, recovery, demolition, and clean-up after the World Trade Center (WTC) disaster on September 11, 2001, were exposed to a complex mixture of airborne smoke, dust, combustion gases, acid mists, and metal fumes. The impact of this exposure on responders' upper and lower respiratory function has been well documented, but little is known about its impact on their sensitivity to odor and irritants.

19 Apr 2010

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.

19 Apr 2010

AKI patients admitted to hospital on a weekend more likely to die: Study

Patients with acute kidney injury who are admitted to the hospital on a weekend are more likely to die than those admitted on a weekday, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. This disparity was most evident in smaller hospitals.

16 Apr 2010

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the Company's New Drug Application (NDA) for the use of Soliris® (eculizumab) as a treatment for patients in Japan with paroxysmal nocturnal hemoglobinuria (PNH).

16 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Kidney Disease News and Research

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

High dose B-vitamin therapy slows progression of diabetic nephropathy: Study

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

High levels of phosphate in sodas accelerate signs of aging

New DaVita Phosphorus Challenge tool for CKD and dialysis patients

Black children with chronic kidney disease have severe anemia than white children: Study

LFA seeks grant applications from medical researchers to help advance understanding of lupus nephritis

Ampio Pharmaceuticals signs LOI to acquire DMI Biosciences

Mandatory cuts for salt content in processed foods on the horizon

Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies

Tips on how to live joyful life with a chronic disease now available in audio version

More testimony on Patel trial

Kaiser Permanente physician to receive ASH Marvin Moser Clinical Hypertension Award

CorMedix receives patent for Neutrolin

RANKL inhibition may prove effective in treatment of human malignancy, suggests study

Exposure to dust after WTC collapse impairs ability to detect odors and sense irritants

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

AKI patients admitted to hospital on a weekend more likely to die: Study

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News